Pancreatic Adenocarcinoma Clinical Trial
Official title:
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
Histological proof is a crucial and necessary step for appropriate care in oncology. In the
case of pancreatic cancer, histological proof from pathological analysis of the surgical
specimen is very rare due to the limited number (15-20 %) of localized tumor accessible to
surgical resection. In most cases, invasive endoscopic explorations are necessary for
histological diagnosis before deciding of the most appropriate treatment (palliative
chemotherapy or radiochemotherapy). The endoscopic ultrasound with fine needle aspiration
(EUS-FNA) is currently considered as the first-line endoscopic procedure for the cytological
diagnosis of solid pancreatic tumors. The technique is performed under general anesthesia
with sensitivity for the diagnosis of adenocarcinoma of 80% in case of a single procedure and
92% in situations where three different procedures are required. EUS-FNA has to be performed
by a physician properly trained for this type of interventional endoscopy. Some severe
complications may occur but are relatively rare in expert centers (bleeding, perforation,
complications of general anesthesia ...).
Diagnostic alternative approach is biological with research in the peripheral blood of
markers of tumor disease. It is possible to detect indirect markers which are molecules
produced by tumor tissue (eg CA19.9) and direct markers which reflect the presence of tumor
biological material (circulating tumor cells (CTCs) or circulating tumor DNA).
The value of detection of CTCs is not determined for the diagnostic and therapeutic
management of pancreatic cancer. Indeed, no study has evaluated the diagnosis performance of
circulating markers with EUS-FNA, the reference method for the diagnosis of unresectable
forms.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
| Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
| Completed |
NCT01959672 -
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT03673423 -
Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer
|
||
| Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Completed |
NCT03054987 -
Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction
|
N/A | |
| Terminated |
NCT02345460 -
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
|
Phase 2 | |
| Completed |
NCT02174887 -
Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT03703063 -
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
|
Phase 1 | |
| Terminated |
NCT04077372 -
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
|
N/A | |
| Recruiting |
NCT03073785 -
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT03665441 -
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC
|
Phase 3 | |
| Recruiting |
NCT04627246 -
Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06217666 -
Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)
|
Phase 1 | |
| Recruiting |
NCT05585320 -
A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT04119362 -
PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
|
||
| Completed |
NCT03105921 -
Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma
|
N/A | |
| Not yet recruiting |
NCT05287347 -
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
|
||
| Withdrawn |
NCT02592395 -
Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma
|
Phase 1 |